Study says screening accounts for much of black/white disparity in colorectal cancer

May 3, 2012, American Cancer Society

A new study finds differences in screening account for more than 40 percent of the disparity in colorectal cancer incidence and nearly 20 percent of colorectal cancer mortality between blacks and whites. Differences in stage-specific survival, which likely reflect differences in treatment account for additional 35% of the black-white disparity in colorectal cancer mortality rates. The study, appearing early online in Cancer Epidemiology Biomarkers and Prevention, concludes that equal access to care could substantially reduce the racial disparities in colorectal cancer (CRC) rates.

Previous studies have identified considerable disparities in CRC incidence and mortality rates between blacks and whites in the United States. For the new study, researchers led by Iris Lansdorp-Vogelaar, a visiting scientist at the American Society when this project was conceived and developed , and now with Erasmus Medical Center, Rotterdam, The Netherlands, used a computer simulation model to apply the screening and survival rates seen among whites to the population of black Americans 50 and over, then compared those to actual, "observed" incidence and mortality rates in blacks to calculate how much of the existing in CRC rates are attributable to differences in screening and/or stage-specific relative survival.

They found that applying the screening pattern observed among whites to blacks would close the disparity gap in CRC incidence rates in age 50 and older from 28.2 to 16.4 cases per 100,000. Screening would decrease the mortality gap from 26.8 to 21.6 deaths per 100,000. If blacks had the stage-specific relative survival of whites, the disparity in CRC mortality rates would decrease even further, to 17.2 deaths per 100,000. And when combined, the screening pattern and stage-specific relative CRC survival of whites would decrease disparity in CRC mortality to 12.4 deaths per 100,000.

The report finds differences in CRC screening explained 42% of the observed disparity in CRC incidence between blacks and whites and 19% of disparity in CRC mortality. Stage specific relative CRC survival differences explained 36% of the disparity in CRC mortality. Together, according to the study, differences in screening and survival explained 54% of disparity in CRC mortality. The authors say equalizing access to care could substantially reduce the racial disparities in CRC burden.

As for the remaining 46% to 58% of the disparity in CRC incidence and mortality, known or unknown lifestyle factors are the most likely candidates for the gap. Those include alcohol, smoking, obesity, and meat consumption, which increase the risk of CRC, as well as physical activity and postmenopausal hormone replacement therapy (in women), which decrease risk.

Explore further: Study finds colorectal cancer mortality dropping slower in African Americans

More information: doi:10.1158/1055-9965.EPI-12-0023

Related Stories

Study finds colorectal cancer mortality dropping slower in African Americans

December 22, 2011
A new study finds that while colorectal cancer mortality rates dropped in the most recent two decades for every stage in both African Americans and whites, the decreases were smaller for African Americans, particularly for ...

Single flexible sigmoidoscopy screening associated with reduced colorectal cancer

August 18, 2011
A single flexible sigmoidoscopy screening between the ages of 55-64 years is associated with a lower level of colorectal cancer (CRC) incidence and mortality, according to a study published online August 18 in the Journal ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.